Animal Model of Chronic Migraine‐Associated Pain

Laura S. Moye1, Amynah A. A. Pradhan1

1 Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois
Publication Name:  Current Protocols in Neuroscience
Unit Number:  Unit 9.60
DOI:  10.1002/cpns.33
Online Posting Date:  July, 2017
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library


Migraine is a debilitating condition that affects hundreds of millions of people worldwide. A subset of these patients experience chronic migraine, resulting in long‐term disability and a severely lowered quality of life. The development of novel migraine therapies has been slow, partially due to the small number of predictive animal models. We have recently developed a novel model of chronic migraine‐associated pain, using the known human migraine trigger, nitroglycerin. Injection of nitroglycerin evokes an acute mechanical hyperalgesia, which is sensitive to the acute migraine therapy sumatriptan. In addition, chronic administration of nitroglycerin produces a progressive and sustained decrease in basal mechanical responses, and this hypersensitivity is blocked by migraine preventatives such as topiramate. This mouse model of chronic migraine can be used to study the mechanisms underlying progression of migraine from an episodic to a chronic disorder, and for identifying and screening novel acute and preventive migraine therapies. © 2017 by John Wiley & Sons, Inc.

Keywords: headache; hyperalgesia; nitric oxide; nitroglycerin; rodent; pain

PDF or HTML at Wiley Online Library

Table of Contents

  • Commentary
  • Literature Cited
  • Figures
PDF or HTML at Wiley Online Library


Basic Protocol 1:

  • C57BL/6 mice, 8‐24 weeks old, group housed
  • 5 mg/ml nitroglycerin (NTG; e.g., American Regent, NDC# 0517‐4810‐25)
  • Saline (0.9% NaCl)
  • Animal colony/vivarium
  • Behavioral testing room containing:
    • von Frey mesh stand (e.g., IITC Life Science, part no. 410)
    • Mouse plexiglass testing boxes (e.g., IITC Life Science, part no. 433)
  • Diaper/absorbent pads
  • Permanent marker
  • 5‐ml or 15‐ml tubes
  • von Frey filaments (weight in grams/size: 0.008/1.65, 0.04/2.44, 0.07/2.83, 0.16/3.22, 0.4/3.61, 0.6/3.84, 1/4.08, 2/4.31; e.g., Bioseb Bio‐VF‐M or Stoelting Touch Test Sensory Probes)
  • 1‐ml syringes with slip tip, sterile
  • 26 G, 1/2 in. needles, sterile
  • Digital scale
  • Timer
NOTE: All protocols using live animals must first be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC) or must conform to governmental regulations regarding the care and use of laboratory animals.
PDF or HTML at Wiley Online Library



Literature Cited

Literature Cited
  Afridi, S. K., Matharu, M. S., Lee, L., Kaube, H., Friston, K. J., Frackowiak, R. S., & Goadsby, P. J. (2005). A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain, 128, 932–939. doi: 10.1093/brain/awh416.
  Bates, E. A., Nikai, T., Brennan, K. C., Fu, Y. H., Charles, A. C., Basbaum, A. I., … Ahn, A. H. (2010). Sumatriptan alleviates nitroglycerin‐induced mechanical and thermal allodynia in mice. Cephalalgia, 30, 170–178. doi: 10.1111/j.1468‐2982.2009.01864.x.
  Bigal, M. E., Ashina, S., Burstein, R., Reed, M. L., Buse, D., Serrano, D., & Lipton, R. B. (2008). Prevalence and characteristics of allodynia in headache sufferers: A population study. Neurology, 70, 1525–1533. doi: 10.1212/01.wnl.0000310645.31020.b1.
  Bigal, M. E., Serrano, D., Reed, M., & Lipton, R. B. (2008). Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology, 71, 559–566. doi: 10.1212/01.wnl.0000323925.29520.e7.
  Brennan, K. C., Bates, E. A., Shapiro, R. E., Zyuzin, J., Hallows, W. C., Huang, Y., … Ptacek, L. J. (2013). Casein kinase idelta mutations in familial migraine and advanced sleep phase. Science Translational Medicine, 5, 183ra156. doi: 10.1126/scitranslmed.3005784.
  Burstein, R., Collins, B., & Jakubowski, M. (2004). Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Annals of Neurology, 55, 19–26. doi: 10.1002/ana.10786.
  Burstein, R., Jakubowski, M., Garcia‐Nicas, E., Kainz, V., Bajwa, Z., Hargreaves, R., … Borsook, D. (2010). Thalamic sensitization transforms localized pain into widespread allodynia. Annals of Neurology, 68, 81–91. doi: 10.1002/ana.21994.
  Capuano, A., Greco, M. C., Navarra, P., & Tringali, G. (2014). Correlation between algogenic effects of calcitonin‐gene‐related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin‐induced sensitization. European Journal of Pharmacology, 740, 97–102. doi: 10.1016/j.ejphar.2014.06.046.
  Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994). Quantitative assessment of tactile allodynia in the rat paw. Journal Neuroscience Methods, 53, 55–63. doi: 10.1016/0165‐0270(94)90144‐9.
  Charles, A., & Brennan, K. C. (2008). A touch of increased pain: Cutaneous allodynia in migraine. Annals of Neurology, 63, 130‐132. doi: 10.1002/ana.21323.
  Christiansen, I., Thomsen, L. L., Daugaard, D., Ulrich, V., & Olesen, J. (1999). Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia, 19, 660–667. doi: 10.1046/j.1468‐2982.1999.019007660.x.
  Dixon, W. J. (1965). The up‐and‐down method for small samples. Journal of the American Statistical Association, 60, 967–978. doi: 10.2307/2283398.
  Erdener, S. E., & Dalkara, T. (2014). Modelling headache and migraine and its pharmacological manipulation. British Journal of Pharmacology, 171, 4575–4594. doi: 10.1111/bph.12651.
  Farajdokht, F., Babri, S., Karimi, P., & Mohaddes, G. (2016). Ghrelin attenuates hyperalgesia and light aversion‐induced by nitroglycerin in male rats. Neuroscience Letters, 630, 30–37. doi: 10.1016/j.neulet.2016.07.026.
  Greco, R., Meazza, C., Mangione, A. S., Allena, M., Bolla, M., Amantea, D., … Tassorelli, C. (2011). Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts. Cephalalgia, 31, 190–198. doi: 10.1177/0333102410379887.
  ICHD. (2013). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia, 33, 629–808. doi: 10.1177/0333102413485658.
  Iversen, H. K., Olesen, J., & Tfelt‐Hansen, P. (1989). Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain, 38, 17–24. doi: 10.1016/0304‐3959(89)90067‐5.
  Markovics, A., Kormos, V., Gaszner, B., Lashgarara, A., Szoke, E., Sandor, K., … Helyes, Z. (2012). Pituitary adenylate cyclase‐activating polypeptide plays a key role in nitroglycerol‐induced trigeminovascular activation in mice. Neurobiology of Disease, 45, 633–644. doi: 10.1016/j.nbd.2011.10.010.
  Olesen, J. (2008). The role of nitric oxide (NO) in migraine, tension‐type headache and cluster headache. Pharmacology & Therapeutics, 120, 157–171. doi: 10.1016/j.pharmthera.2008.08.003.
  Olesen, J. (2010). Nitric oxide‐related drug targets in headache. Neurotherapeutics, 7, 183–190. doi: 10.1016/j.nurt.2010.03.006.
  Pradhan, A. A., Smith, M. L., Zyuzin, J., & Charles, A. (2014). delta‐Opioid receptor agonists inhibit migraine‐related hyperalgesia, aversive state and cortical spreading depression in mice. British Journal of Pharmacology, 171, 2375–2384. doi: 10.1111/bph.12591.
  Pradhan, A. A., Smith, M. L., McGuire, B., Tarash, I., Evans, C. J., & Charles, A. (2014). Characterization of a novel model of chronic migraine. Pain, 155, 269‐274. doi: 10.1016/j.pain.2013.10.004.
  Stewart, W. F., Wood, C., Reed, M. L., Roy, J., & Lipton, R. B. (2008). Cumulative lifetime migraine incidence in women and men. Cephalalgia, 28, 1170–1178. doi: 10.1111/j.1468‐2982.2008.01666.x.
  Stovner, L., Hagen, K., Jensen, R., Katsarava, Z., Lipton, R., Scher, A., … Zwart, J. A. (2007). The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia, 27, 193–210. doi: 10.1111/j.1468‐2982.2007.01288.x.
  Sufka, K. J., Staszko, S. M., Johnson, A. P., Davis, M. E., Davis, R. E., & Smitherman, T. A. (2016). Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats. The Journal of Headache and Pain, 17, 40. doi: 10.1186/s10194‐016‐0624‐y.
  Tipton, A. F., Tarash, I., McGuire, B., Charles, A., & Pradhan, A. A. (2015). The effects of acute and preventive migraine therapies in a mouse model of chronic migraine. Cephalalgia, [ePub ahead of print]. doi: 10.1177/0333102415623070.
  Victor, T. W., Hu, X., Campbell, J. C., Buse, D. C., & Lipton, R. B. (2010). Migraine prevalence by age and sex in the United States: A life‐span study. Cephalalgia, 30, 1065–1072. doi: 10.1177/0333102409355601.
  Yuen, P. H., Denman, S. L., Sokoloski, T. D., & Burkman, A. M. (1979). Loss of nitroglycerin from aqueous solution into plastic intravenous delivery systems. Journal of Pharmaceutical Sciences, 68, 1163–1166. doi: 10.1002/jps.2600680928.
PDF or HTML at Wiley Online Library